Randomised Phase II Study comparing, as first-line chemotherapy, single-agent Oral Vinorelbine administered with two different schedules in patients with Advanced Breast Cancer
Randomised Phase II Study comparing, as first-line chemotherapy, single-agent Oral Vinorelbine administered with two different schedules in patients with Advanced Breast Cancer
TEMPOBREAST 01
Randomised Phase II Study comparing, as first-line chemotherapy, single-agent Oral Vinorelbine administered with two different schedules in patients with Advanced Breast Cancer
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
-
Gender
Female
Therapeutic area :
Oncology
Disease :
Breast cancer
Study medication :
Vinorelbine (Navelbine® Oral)
Phase :
Phase II
Start Date :
03 August 2015
End date :
28 September 2020
Study ID :
PM 0259 CA 233 B0
EudraCT/CTIS number :
2014-003860-19
Send by email